OncoMasTR
OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0OncoMasTR project word cloud
Explore the words cloud of the OncoMasTR project. It provides you a very rough idea of what is the project "OncoMasTR" about.
Project "OncoMasTR" data sheet
The following table provides information about the project.
| Coordinator |
ONCOMARK LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.oncomastr.com |
| Total cost | 2˙751˙250 € |
| EC max contribution | 2˙751˙250 € (100%) |
| Programme |
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 2. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2015 |
| Funding Scheme | SME-2 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-02-01 to 2018-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ONCOMARK LIMITED | IE (DUBLIN) | coordinator | 2˙751˙250.00 |
Map
Project objective
OncoMark Ltd are developing a novel, game-changing breast cancer prognostic assay, called OncoMasTR, which has the potential to transform clinical practice and patient care. OncoMasTR will help clinicians to decide which patients should receive chemotherapy for early stage breast cancer, which is a pressing clinical and economic issue worldwide. OncoMasTR is more cost-effective than competitor assays, demonstrates superior performance clinically, generates a user-friendly binary (yes/no) output and can be carried out on-site using standard equipment. Our principal aim is to develop OncoMasTR as a CE marked kit, and penetrate a global market.
OncoMasTR comprises a novel panel of biomarkers of tumour progression, measured by qRT-PCR using standard procedures and equipment. Objectives for Phase 2 are to analytically, clinically and commercially validate the OncoMasTR prototype under ISO13485 standards, using two large cohorts of breast cancer patients. Access to tissues from a prospective clinical trial will enable us to benchmark OncoMasTR’s performance against the leading competitor assay. Communication and dissemination of data will be key to building a strong base of OncoMasTR ambassadors in the clinical arena, and to leverage private investment in OncoMark for development of other products in our pipeline. OncoMasTR will bring OncoMark into the clinical biomarker arena and will positively impact healthcare costs in the EU and globally.
Deliverables
| Launch of project webpage | Websites, patent fillings, videos etc. | 2019-05-30 15:02:58 |
Take a look to the deliverables list in detail: detailed list of OncoMasTR deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Barron S, Jirström K, Jernström H, Ingvar C, Moran B, Wang C-JA, Loughman T, Fender B, Dynoodt P, Lopez-Ruiz C, Russell N, Gallagher WM Prognostic value of OncoMasTR: A novel multigene signature based on master transcriptional regulators published pages: , ISSN: , DOI: |
SABCS Abstract Book | 2019-06-13 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOMASTR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCOMASTR" are provided by the European Opendata Portal: CORDIS opendata.